.png?width=1472&height=390&name=Metabolomycs%20Logo%20(4).png)
About us
Energy is Life!
We would you like to offer you and your existing clients our NextGen Metabolomic testing that identifies a wide variety of blood metabolites in order to identify potential diseases and to improve their metabolism and energy levels.
We use Mass Spectrometry and AI software to generate a report that you can share with your clients and help prevent diseases before they cause irreversible organ damage or other health problems. Identification and prevention is one of the keys to a long and healthy life.
Our story
Our research found that from cancer to Covid, diabetes to dementia virtually every disease reflects a state of alerted metabolism.
Following the landmark observations of Sir Archibald Garrod who defined Inborn Errors of Metabolism (1909) we found subtle potentially addressable “Inborn-Like” errors of metabolism in the blood of many otherwise healthy patients.
In 2018, our Dr. da Silva published an important paper......
Our mission
Our mission is to provide the health and wellness community and its practitioners with a cutting-edge tool to guide patients to optimal health by identifying problems before they adversely impact their overall health.
Our history
Our founder Dr. Robert Nagourney, CEO of Nagourney Cancer Institute teamed up with Dr. Ismael Dale Cotrim da SIlva from Sao Paulo, Brazil and pulled together a team of experts in various disciplines to form our parent company, Metabolomycs.
Our medical team has published clinical trials with UC Irvine and Federal University of Sao Paulo, Brazil. Overall, they have published 24 papers and 8 research abstracts from 2013 to 2024 on cancer and metabolomics.
We have been granted 9 US patents in cancer detection and metabolomic analysis with additional issued patents in Canada and 11 other countries
Our Science Team
Under the leadership of Dr. Robert Nagourney, our team has amassed decades of experience in Oncology, Hematology, Molecular biology, Metabolomics and Mass spectrometry.
Robert A. Nagourney, MD
CEO and Founder
CEO of Nagourney Cancer Institute is an Internationally
recognized pioneer in cancer research and personalized cancer treatment.
Dr. Nagourney has been featured on CNN, ABC World News Tonight, CNBC, Wall Street Journal and has been a TEDx speaker.
Ismael Dale Cotrim da Silva, MD, PhD
Co-Founder
Senior Advisor and Coordinator of Molecular Biology at Fleury Laboratories. Holds several international patents in cancer and non-malignant diseases.
He has published 200+peer-reviewed articles and holds two international patents on breast cancer and HIV.
Paulo D'Amora, MD, PhD
Senior Scientist
Award-winning researcher from Sao Paulo State Research Foundation; Directs research on NextGen Metabolomics between US and Brazil research centers.
He has experience in Cellular and Molecular Biology, Biochemistry and Metabolomics applied to Oncology and Biomarker Discovery.
Steve Evans
Senior Scientist
COO, Nagourney Cancer Institute, Former Senior Research Scientist at Todd Cancer Institute, Long Beach, CA
Steve has experience in spectrophotometry and mass spectrometry and has published over 70 manuscripts, book chapters and abstracts.
Rhoderic Bannatyne
Chief Financial Officer
Auditor with KPMG UK; experience with SaaS & Biotech ventures in Europe & US.
Glenn Bernstein
Director of Marketing
Former Marketing Director at Nagourney Cancer Institute, Regional Sales Manager. at American Home Shield, Senior Business Strategist improving companies throughout US, Canada.
Glenn holds a B.A. in Mathematics-Statistics and an MBA from Pepperdine University, CA
Company news
We now have a fully operational satellite laboratory in Campo Grande, Brazil